Capricor Therapeutics (CAPR) shares were down nearly 49% pre-bell Friday after the company said that the US Food and Drug Administration has required additional clinical data on deramiocel, a cell therapy candidate for cardiomyopathy in Duchenne muscular dystrophy patients.
Q32 Bio (QTTB) shares were 31% lower, erasing part of Thursday's rally.
Concorde International (CIGL) stock was down 28%, extending Thursday's slide.